List view / Grid view
10 December 2014 | By Alizé Pharma SAS
Based on these results, a Phase Ib trial has been launched in type 2 diabetes patients...
8 December 2014 | By Codexis
Codexis, Inc. announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration...
8 December 2014 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166...
4 December 2014 | By reViral
Second tranche of Seeding Drug Discovery award from Wellcome Trust Innovations...
3 December 2014 | By Alizé Pharma III SAS
Dr. David Clemmons, co-inventor of the technology and a highly reputable key opinion leader in endocrinology and metabolism, will collaborate on the drug optimization and development programs...
3 December 2014 | By Evotec
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.
2 December 2014 | By BioVersys and Enamine
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year...
2 December 2014 | By MRC Technology
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug...
2 December 2014 | By The Medical Research Council
Medical Research Council scientists have created the world’s first enzymes made from artificial genetic material...
2 December 2014 | By The International College of Neuropsychopharmacology
The International College of Neuropsychopharmacology (CINP) has published a paper in Nature Reviews Drug Discovery on how global governments must act to address the dearth of new drugs for central nervous system (CNS) diseases...
1 December 2014 | By ABIVAX
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.,,
25 November 2014 | By LaVison BioTec
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Peter Friedl and his imaging of cancer growth using intravital microscopy...
25 November 2014 | By The Lead South Australia
New drugs and treatment strategies will be developed from research that provides a new understanding of how bacterial toxins target human cells...
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
24 November 2014 | By MRC Technology / Yabao Pharmaceuticals
MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...
